Cancers, Vol. 11, Pages 981: Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
Cancers, Vol. 11, Pages 981: Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
Cancers doi: 10.3390/cancers11070981
Authors:
Fabiana Napolitano
Luigi Formisano
Alessandro Giardino
Roberto Girelli
Alberto Servetto
Antonio Santaniello
Francesca Foschini
Roberta Marciano
Eleonora Mozzillo
Anna Chiara Carratù
Priscilla Cascetta
Pietro De Placido
Sabino De Placido
Roberto Bianco
The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) affects the clinical outcome in these patients. LAPC patients treated at our institution were retrospectively analysed to reach this goal. The group characteristics were similar: 35 patients were treated with the FOLFIRINOX regimen and 21 patients with Gemcitabine Nab-Paclitaxel. The number of patients undergoing surgery was 14 in the FFN group (40%) and six in the GemNab group (28.6%). The median Disease-Free Survival (DFS) was 77.10 weeks in the FFN group and 58.65 weeks in the Gem Nab group (p = 0.625), while the median PFS in the unresected group was 49.4 weeks in the FFN group and 30.9 in the GemNab group (p = 0.0029, 95% CI 0.138–0.862, HR 0.345). The overall survival (OS) in the resected...
Source: Cancers - Category: Cancer & Oncology Authors: Fabiana Napolitano Luigi Formisano Alessandro Giardino Roberto Girelli Alberto Servetto Antonio Santaniello Francesca Foschini Roberta Marciano Eleonora Mozzillo Anna Chiara Carrat ù Priscilla Cascetta Pietro De Placido Sabino De Placido Roberto Bianco Tags: Article Source Type: research